Enhancing PARP inhibitor treatment efficacy for urothelial carcinoma by new biomarkers and synergistic combination treatment with bromodomain protein inhibitor PLX51107

We characterized cellular and molecular effects of the PARP inhibitor (PARPi) Olaparib compared to Talazoparib in bladder cancer cell lines and their Cisplatin pre-treated sublines. We aimed to identify common target genes of both PARPi and differences in mechanism of action to understand resistance mechanisms and identify new PARPi response marker for bladder cancer. RNA was submitted to RNA sequencing analysis on the NextSeq2000 system (Illumina). Total RNA from urothelial carcinoma (UC) cell lines T24, T24 Cisplatin resistant cells (LTT), J82, J82LTT and RT112 cells treated with PARPI Olaparib or Talazoparib for 72h and compared to solvent control (DMSO). Triplicates were analysed for each condition.